University of California San Francisco
Helen Diller Family Comprehensive Cancer Center
Terence Friedlander, MD

Terence Friedlander, MD

Chief of Hematology-Oncology at Zuckerberg San Francisco General; Associate Director of the HDFCCC at ZSFG; Associate Clinical Professor, Division of Hematology/Oncology, UCSF

Cancer Center Program Memberships

Prostate Cancer

Research Summary

I am a clinical and translational oncologist specializing in cancers of the genitourinary tract, specifically bladder and prostate cancers. My research is focused on understanding the basic biology these malignancies and in developing novel therapeutic ways to treat disease. I have collaborated with Dr. Pamela Paris over the last 6 years investigating advanced prostate and bladder cancer, particularly exploring the predictive value of circulating tumor cells (CTCs) in these malignancies. In addition to our work exploring CTCs as biomarkers of response and resistance, we have studied the structural and epigenetic state of advanced prostate cancer, and this work has led to a number of grants and publications. As a clinical academic oncologist I serve as principal investigator or co-investigator on a number clinical trials in advanced prostate and bladder cancer, which allows us to recruit patients for much of our biomarker work. This collaboration spans from the bench to the bedside, and I hope this work will help us to be able to predict which are likely to respond to neoadjuvant chemotherapy and allow us to tailor our clinical strategy to avoid giving toxic and ineffective therapies, and to select patients most likely to benefit.

Education

Brown University, BA, 5/99
New York University School of Medicine, 2003, MD
UCSF Medical Center, 2003-2006, Residency
Utrecht University, Netherlands, 2007, Medical Ethics
UCSF Medical Center, 2007-2010, Oncology Fellowship


Professional Experience

  • 2009-2010
    Chief Fellow, Hematology and Oncology, UCSF
  • 2010-2011
    Clinical Fellowship in Urologic Oncology
  • 2011-current
    Assistant Clinical Professor, Division of Hematology/Oncology, UCSF

Honors & Awards

  • 2006
    Fullbright Scholarship in Medical Ethics, Netherlands-America Foundation
  • 2010
    ASCO Young Investigator Award, American Society of Clinical Oncology
  • 2011
    ASCO Merit Award, American Society of Clinical Oncology
  • 2012
    Physician Research Training Aaward, United States Department of Defense
  • 2012
    Young Investigator Award, Prostate Cancer Foundation
  • 2012
    Young Investigator Travel Award, Advances in Circulating Tumor Cells Symposium

Selected Publications

  1. Wei XX, Siegel AP, Aggarwal R, Lin AM, Friedlander TW, Fong L, Kim W, Louttit M, Chang E, Zhang L, Ryan CJ. A Phase II Trial of Selinexor, an Oral Selective Inhibitor of Nuclear Export Compound, in Abiraterone- and/or Enzalutamide-Refractory Metastatic Castration-Resistant Prostate Cancer. Oncologist. 2018 Feb 27.
    View on PubMed
  2. Zhu J, Armstrong AJ, Friedlander TW, Kim W, Pal SK, George DJ, Zhang T. Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond. J Immunother Cancer. 2018 Jan 25; 6(1):4.
    View on PubMed
  3. Lindquist KJ, Sanford T, Friedlander TW, Paris PL, Porten SP. Copy number gains at chr3p25 and chr11p11 are associated with lymph node involvement and survival in muscle-invasive bladder tumors. PLoS One. 2017; 12(11):e0187975.
    View on PubMed
  4. Almassi N, Reichard C, Li J, Russell C, Perry J, Ryan CJ, Friedlander T, Sharifi N. HSD3B1 and Response to a Nonsteroidal CYP17A1 Inhibitor in Castration-Resistant Prostate Cancer. JAMA Oncol. 2017 Oct 12.
    View on PubMed
  5. Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Clark PE, Downs TM, Efstathiou JA, Flaig TW, Friedlander T, Greenberg RE, Guru KA, Hahn N, Herr HW, Hoimes C, Inman BA, Jimbo M, Kader AK, Lele SM, Meeks JJ, Michalski J, Montgomery JS, Pagliaro LC, Pal SK, Patterson A, Plimack ER, Pohar KS, Porter MP, Preston MA, Sexton WJ, Siefker-Radtke AO, Sonpavde G, Tward J, Wile G, Dwyer MA, Gurski LA. Bladder Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017 Oct; 15(10):1240-1267.
    View on PubMed
  6. Powles T, O'Donnell PH, Massard C, Arkenau HT, Friedlander TW, Hoimes CJ, Lee JL, Ong M, Sridhar SS, Vogelzang NJ, Fishman MN, Zhang J, Srinivas S, Parikh J, Antal J, Jin X, Gupta AK, Ben Y, Hahn NM. Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results From a Phase 1/2 Open-label Study. JAMA Oncol. 2017 Sep 14; 3(9):e172411.
    View on PubMed
  7. Friedlander TW, Graff JN, Zejnullahu K, Anantharaman A, Zhang L, Paz R, Premasekharan G, Russell C, Huang Y, Kim W, Aggarwal RR, Lin AM, Fong L, Alumkal JJ, Beer TM, Sharifi N, Alyamani M, Dittamore R, Small EJ, Paris PL, Ryan CJ. High-Dose Abiraterone Acetate in Men With Castration Resistant Prostate Cancer. Clin Genitourin Cancer. 2017 Dec; 15(6):733-741.e1.
    View on PubMed
  8. Wei XX, Hsieh AC, Kim W, Friedlander T, Lin AM, Louttit M, Ryan CJ. A Phase I Study of Abiraterone Acetate Combined with BEZ235, a Dual PI3K/mTOR Inhibitor, in Metastatic Castration Resistant Prostate Cancer. Oncologist. 2017 May; 22(5):503-e43.
    View on PubMed
  9. Aggarwal R, Bryce A, Ryan CJ, Harzstark A, Derleth C, Kim W, Friedlander T, Lin AM, Rodvelt-Bagchi T, Dhawan M, Zhang L, Lee M, Siebeneck E, Hough J, Small EJ. A multicenter phase I study of cabazitaxel, mitoxantrone, and prednisone for chemotherapy-naïve patients with metastatic castration-resistant prostate cancer: A department of defense prostate cancer clinical trials consortium study. Urol Oncol. 2017 Apr; 35(4):149.e7-149.e13.
    View on PubMed
  10. Friedlander TW, Pritchard CC, Beltran H. Personalizing Therapy for Metastatic Prostate Cancer: The Role of Solid and Liquid Tumor Biopsies. Am Soc Clin Oncol Educ Book. 2017; 37:358-369.
    View on PubMed
  11. Clark PE, Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Efstathiou JA, Flaig TW, Friedlander T, Greenberg RE, Guru KA, Hahn N, Herr HW, Hoimes C, Inman BA, Kader AK, Kibel AS, Kuzel TM, Lele SM, Meeks JJ, Michalski J, Montgomery JS, Pagliaro LC, Pal SK, Patterson A, Petrylak D, Plimack ER, Pohar KS, Porter MP, Sexton WJ, Siefker-Radtke AO, Sonpavde G, Tward J, Wile G, Dwyer MA, Smith C. NCCN Guidelines Insights: Bladder Cancer, Version 2.2016. J Natl Compr Canc Netw. 2016 10; 14(10):1213-1224.
    View on PubMed
  12. Wei XX, Chan S, Kwek S, Lewis J, Dao V, Zhang L, Cooperberg MR, Ryan CJ, Lin AM, Friedlander TW, Rini B, Kane C, Simko JP, Carroll PR, Small EJ, Fong L. Systemic GM-CSF Recruits Effector T Cells into the Tumor Microenvironment in Localized Prostate Cancer. Cancer Immunol Res. 2016 11; 4(11):948-958.
    View on PubMed
  13. Anantharaman A, Friedlander T, Lu D, Krupa R, Premasekharan G, Hough J, Edwards M, Paz R, Lindquist K, Graf R, Jendrisak A, Louw J, Dugan L, Baird S, Wang Y, Dittamore R, Paris PL. Programmed death-ligand 1 (PD-L1) characterization of circulating tumor cells (CTCs) in muscle invasive and metastatic bladder cancer patients. BMC Cancer. 2016 Sep 22; 16(1):744.
    View on PubMed
  14. Premasekharan G, Gilbert E, Okimoto RA, Hamirani A, Lindquist KJ, Ngo VT, Roy R, Hough J, Edwards M, Paz R, Foye A, Sood R, Copren KA, Gubens M, Small EJ, Bivona TG, Collisson EA, Friedlander TW, Paris PL. An improved CTC isolation scheme for pairing with downstream genomics: Demonstrating clinical utility in metastatic prostate, lung and pancreatic cancer. Cancer Lett. 2016 09 28; 380(1):144-52.
    View on PubMed
  15. Anantharaman A, Friedlander TW. Targeting the androgen receptor in metastatic castrate-resistant prostate cancer: A review. Urol Oncol. 2016 08; 34(8):356-67.
    View on PubMed
  16. Anantharaman A, Friedlander TW. A Stepping Stone Toward Personalized Oncology: Genomic Analysis of Circulating Tumor Cells to Guide Management of Metastatic Castration-resistant Prostate Cancer. Eur Urol. 2015 Dec; 68(6):946-8.
    View on PubMed
  17. Alva A, Friedlander T, Clark M, Huebner T, Daignault S, Hussain M, Lee C, Hafez K, Hollenbeck B, Weizer A, Premasekharan G, Tran T, Fu C, Ionescu-Zanetti C, Schwartz M, Fan A, Paris P. Circulating Tumor Cells as Potential Biomarkers in Bladder Cancer. J Urol. 2015 Sep; 194(3):790-8.
    View on PubMed
  18. Anantharaman A, Friedlander TW. The double-edged sword of ADT: emerging evidence of cardiovascular, pulmonary, and renal risks. Oncology (Williston Park). 2015 Jan; 29(1):67-8.
    View on PubMed
  19. Kim W, Zhang L, Wilton JH, Fetterly G, Mohler JL, Weinberg V, Morse A, Szmulewitz RZ, Friedlander TW, Fong L, Lin AM, Harzstark AL, Molina A, Small EJ, Ryan CJ. Sequential use of the androgen synthesis inhibitors ketoconazole and abiraterone acetate in castration-resistant prostate cancer and the predictive value of circulating androgens. Clin Cancer Res. 2014 Dec 15; 20(24):6269-76.
    View on PubMed
  20. Friedlander TW, Fong L. The end of the beginning: circulating tumor cells as a biomarker in castration-resistant prostate cancer. J Clin Oncol. 2014 Apr 10; 32(11):1104-6.
    View on PubMed

Go to UCSF Profiles, powered by CTSI